DOCSLIB.ORG

761070Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
761070Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761070Orig1s000 NON-CLINICAL REVIEW(S) Tertiary Pharmacology/Toxicology Review Date: November 1, 2017 From: Timothy J. McGovern, PhD, ODE Associate Director for Pharmacology and Toxicology, OND IO BLA: 761070 Agency receipt date: November 16, 2016 Drug: FASENRA (benralizumab) injection, for subcutaneous use Sponsor: AstraZeneca Pharmaceuticals LP Indication: Add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Reviewing Division: Division of Pulmonary, Allergy, and Rheumatology Products The primary pharmacology/toxicology reviewer and team leader concluded that the nonclinical data for FASENRA (benralizumab) solution for subcutaneous injection support approval for the indication listed above. Benralizumab is a humanized, afucosylated IgG1 kappa monoclonal antibody that targets interleukin-5 receptor alpha. The recommended dose of benralizumab is 30 mg administered once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter. The Established Pharmacologic Class (EPC) for benralizumab is “interleukin- 5 receptor alpha-directed cytolytic monoclonal antibody”. Pivotal nonclinical studies were conducted in Cynomolgus monkeys. In toxicology studies up to 39 weeks duration, NOAELs of 10 mg/kg IV and 30 mg/kg SC were identified. The primary finding at a dose of 25 mg/kg IV was a post-dose reaction in one high-dose female that included bruising in the areas of the eyes, face, chest and lower abdomen, a decrease in platelet counts, and abnormal erythrocytes after the fourth dose. The NOAEL doses were associated with systemic exposures (AUC) that provided 153- to 271-fold exposure margins compared to the recommended clinical dose. Genetic toxicity studies were not applicable for this therapeutic biologic protein. Carcinogenicity studies were not conducted since rodents are not pharmacologically relevant species. AstraZeneca submitted a carcinogenicity risk assessment that was evaluated by the CDER Executive Carcinogenicity Assessment Committee. The Committee agreed that a carcinogenicity study was not required. Based on a review of the literature by Dr. Robison, the role of eosinophils in tumor development is unclear. The product label will reflect the outcome of this review. The effects of benralizumab on fertility were evaluated in cynomolgus monkeys in the 39-week toxicity study; no drug-related effects were observed. An enhanced pre- and post-natal development studies were conducted with cynomolgus monkeys to evaluate benralizumab’s effects on development. The NOAEL was the high dose of 30 mg/kg IV; associated with exposure that were ~ 310-times the anticipated clinical exposure. Adult 1 Reference ID: 4175200 females and infants demonstrated reduced eosinophil levels. Placental transfer was demonstrated by measuring benralizumab levels in the serum of infants in utero. Conclusion: I agree with the Division pharmacology/toxicology conclusion that this BLA can be approved from the pharmacology/toxicology perspective. The EPC for benralizumab is appropriate. I have discussed labeling issues with the Division and agree with the proposed text. APPEARS THIS WAY ON ORIGINAL 2 Reference ID: 4175200 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- TIMOTHY J MCGOVERN 11/01/2017 Reference ID: 4175200 DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH PHARMACOLOGY/TOXICOLOGY BLA REVIEW AND EVALUATION OF EXTRACTABLES AND LEACHABLES FROM THE CONTAINER CLOSURE SYSTEM (PREFILLED SYRINGE) Application number: 761070 Supporting document/s: SDN #1 and 22 Applicant’s letter date: November 16, 2016 and July 14, 2017 CDER stamp date: November 16, 2016 and July 14, 2017 Product: Benralizumab [Humanized, afucosylated, immunoglobulin (Ig)G1κ mAb that targets IL-5Rα] Indication: Asthma Applicant: AstraZeneca Pharmaceuticals LP One MedImmune Way Gaithersburg MD 20878 Review Division: Pulmonary, Allergy, and Rheumatology Products Reviewer/Team Leader: Timothy W. Robison, Ph.D., D.A.B.T. Division Director: Badrul Chowdhury, M.D., Ph.D. Project Manager: Colette Jackson Template Version: September 1, 2010 Disclaimer 1 Reference ID: 4131961 BLA #761070 Reviewer: Timothy W. Robison, Ph.D., D.A.B.T. TABLE OF CONTENTS 1 EXECUTIVE SUMMARY...........................................................................................5 1.1 INTRODUCTION .....................................................................................................5 1.2 BRIEF DISCUSSION OF NONCLINICAL FINDINGS .......................................................5 1.3 RECOMMENDATIONS .............................................................................................6 2 DRUG INFORMATION..............................................................................................6 2.1 DRUG ..................................................................................................................6 2.2 RELEVANT INDS, NDAS, BLAS AND DMFS............................................................7 2.3 DRUG FORMULATION ............................................................................................7 2.4 COMMENTS ON NOVEL EXCIPIENTS......................................................................10 2.5 COMMENTS ON EXTRACTABLES AND LEACHABLES.................................................10 2.6 PROPOSED CLINICAL POPULATION AND DOSING REGIMEN.....................................11 2.7 REGULATORY BACKGROUND ...............................................................................11 3 STUDIES SUBMITTED...........................................................................................12 3.1 STUDIES REVIEWED ............................................................................................12 3.2 STUDIES NOT REVIEWED.....................................................................................12 3.3 PREVIOUS REVIEWS REFERENCED.......................................................................12 11 INTEGRATED SUMMARY AND SAFETY EVALUATION..................................12 2 Reference ID: 4131961 BLA #761070 Reviewer: Timothy W. Robison, Ph.D., D.A.B.T. Table of Tables Table 1 Composition of the Drug Product ........................................................................8 (b) (4) Table 2 Prefilled syringe (PFS(b) (4) ): primary packaging components .......8 Table 3 Material components of the pre-sterilized syringe barrel.....................................9 Table 4 Material components of the needle safety shield ................................................9 Table 5 Summary of the drug product development ......................................................13 Table 6 Prefilled syringe component surface areas .......................................................16 Table 7 Extraction details for the glass barrel and 29-gauge needle .............................16 (b) (4) Table 8 Extractables profile of the syringe barrel with 29-gauge staked needle (Forced Extraction Study [Stage 1])....................................................................17 Table 9 Extractables profile of the (b) (4)plunger stopper (Forced Extraction Study [Stage 1])..............................................................................................................18 Table 10 Extractables profile of the (b) (4)plunger stopper using isopropanol..19 (b) (4) Table 11 Measurements of isopropanol extractables from the plunger stopper using LC/MS with electrospray positive mode...................................................20 (b) (4) Table 12 Measurements of isopropanol extractables from the plunger stopper using LC/MS with electrospray negative mode .................................................21 (b) (4) Table 13 Extractables profile of the elastomeric needle shield ..........................22 Table 14 Extractables profile of the elastomeric needle shield using isopropanol ........................................................................................................................................22 Table 15 Prefilled syringe buffer simulation study design ..............................................23 Table 16 Prefilled syringe simulation (Stage 2) study: 38-42°C .....................................25 Table 17 Prefilled syringe simulation (Stage 2) study: 23-27°C .....................................26 Table 18 Prefilled syringe simulation (Stage 2) study: 2-8°C .........................................28 Table 19 Elemental impurities limits ..............................................29 (b) (4) Table 20 Sponsor’s Limits for ..............................................29 (b) (4) Table 21 Time points for measurements of elemental impurities, (b) (4) .........................................................................................................................30 (b) (4) Table 22 Leachables results for elemental impurities, from Process 3 commercial lots (Lots 020F15, 021F15, and 004K15) at time points of 0, 6, and 12 months................................................................................................................30
Load more

Recommended publications
  • Original Article HAEMATOPOIETIC THROMBOCYTE PRECURSORS
    Bulgarian Journal of Veterinary Medicine, 2021, 24, No 1, 2231 ISSN 1311-1477; DOI: 10.15547/bjvm.2019-0063 Original article HAEMATOPOIETIC THROMBOCYTE PRECURSORS IN RAT FEMORAL AND STERNAL BONE MARROW D. SULJEVIĆ1, A. HAMZIĆ1, E. ISLAMAGIĆ1, E. FEJZIĆ2 & A. ALIJAGIĆ1 1Department of Biology, Faculty of Science, University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 2Institute for Transfusion Medicine of FBiH, Sarajevo, Bosnia and Herzegovina Summary Suljević, D., A. Hamzić, E. Islamagić, E. Fejzić & A. Alijagić, 2021. Haematopoietic thrombocyte precursors in rat femoral and sternal bone marrow. Bulg. J. Vet. Med., 24, No 1, 2231. This research presents the first findings on thrombopoiesis for Wistar rats. Haemopoietic cells from the femur and the sternum were analysed by light microscopy in combination with infrared and near- ultraviolet light for fine cytoplasmic structure analysis. Five main types of thrombocyte precursor cells were identified in the bone marrow samples: megakaryoblast, promegakaryocyte and megakaryocyte (basophilic, acidophilic and thrombocytogenic). More intensive thrombopoiesis and morphologically differentiated cells were found in sternum samples. Key words: bone marrow, megakaryocyte, platelets, thrombopoiesis, Wistar rat INTRODUCTION Bone marrow smears from rats usually is diminished as platelets production is contain a large number of megakaryocytes shifted from the spleen to some other accounting for 0.40–0.77% of total organ, like bone marrow (Bolliger, 2004). nucleated cells in rat bone marrow (Saad Large megakaryocytes could be a et al., 2000). Density and distribution of product of an early thrombopoietic phase megakaryocytes vary with technique and occurring in the first days of pregnancy as among smears; however, there are no observed in the mammalian order of published results regarding the precise rodents (Rodentia) (Pacheco et al., 2002).
    [Show full text]
  • Platelet and Erythrocyte Functional Defects Caused by Mutations of Transcription Factor GFI1B
    Platelet and erythrocyte functional defects caused by mutations of transcription factor GFI1B Lucinda Beutler A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Faculty of Medicine University of Sydney December 2018 I praise you because…… I am fearfully and wonderfully made; Your works are wonderful - I know that full well. Psalm 139:14 (NIV) TABLE OF CONTENTS STATEMENT OF ORIGINALITY ...................................................................................................... vi ACKNOWLEDGEMENTS .............................................................................................................. vii ABSTRACT ................................................................................................................................... ix PUBLICATIONS AND PRESENTATIONS ........................................................................................... x LIST OF FIGURES .......................................................................................................................... xi LIST OF TABLES........................................................................................................................... xv ABBREVIATIONS ........................................................................................................................ xvii 1. Literature review ...................................................................................................................... 2 1.1 Introduction ......................................................................................................................
    [Show full text]
  • Cardiovascular System
    Cardiovascular System BLOOD PART 2 Leukocytes Make up <1% of total blood volume Defend Diapedesis Formed elements Plasma • 55% of whole blood • Least dense component Buffy coat • Leukocytes and platelets • <1% of whole blood Erythrocytes 1 Withdraw 2 Centrifuge the • 45% of whole blood blood and place blood sample. • Most dense in tube. component Copyright © 2010 Pearson Education, Inc. Figure 17.1 Differential WBC count (All total 4800 – 10,800/l) Five types Formed of WBC’s elements Platelets Granulocytes Neutrophils (50 – 70%) Leukocytes Eosinophils (2 – 4%) Basophils (0.5 – 1%) Erythrocytes Agranulocytes Lymphocytes (25 – 45%) Monocytes (3 – 8%) Figure 17.9 Leukocytes Granulocytes Neutrophils, eosinophils and basophils Cytoplasmic granules Larger and shorter-lived than RBCs Lobed nuclei All phagocytic to some degree (a) Neutrophil; (b) Eosinophil; (c) Basophil; multilobed bilobed nucleus, bilobed nucleus, nucleus red cytoplasmic purplish-black granules cytoplasmic granules Figure 17.10 (a-c) Neutrophils AKA: Polymorphonuclear leukocytes (PMNs) Most numerous WBC Diapedesis Granules contain hydrolytic enzymes Bacteria slayers #’s increase during acute infection Eosinophils Diapedesis Granules Antihistamines Lysozyme like substances Parasites Allergic response Basophils Rare WBC Diapedesis Large, purplish-black granules Histamine Inflammatory chemical vasodilation Attracts other WBC’s to inflamed sites Heparin Prevents clotting (a) Neutrophil; (b) Eosinophil; (c) Basophil; multilobed bilobed nucleus, bilobed
    [Show full text]
  • Continuing Education Independent Study Series
    Continuing Education Independent Study Series DOROTHYCORRIGAN, CST Professional Development Manager Association of Surgical Technologists Englewood, Colorado Association of Surgical Technologists Publication made possible by an educational grant provided by Kimberly-Clark Corporation ASSOCIATION OF SURGICAL Association of Surgical Technologists, Inc. ~(-J-INOU)GISTS7108-C S.Alton Way AEGER PRIMO - Englewood, CO 80112-2106 THEPAnmTTFIRST 303-694-9130 ISBN 0-926805-05-3 Copyrighto 1994 by the Association of Surgical Technologists, Inc. All rights reserved. Printed in the United States of America. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. PREFACE "The Blood" is part of the AST Continuing Education Independent Study Series. The series has been specifically designed for surgical technologists to provide independent study opportunities that are rel- evant to the field and support the educational goals of the profession and the Association. Acknowledgments AST gratefully acknowledges the generous support of Kimberly-Clark Corporation, Roswell, Georgia, without whom this project could not have been undertaken. The Blood Purpose The purpose of this module is to acquaint the learner with the components of blood and their func- tions. Upon completing this module, the learner will receive 2 continuing education (CE) credits in category 1G. Objectives Upon completing this module, the learner will be able to do the following: 1. Describe the function of blood. 2. Identify the formed elements of blood and their functions. 3. Identify the components of plasma and their functions.
    [Show full text]
  • The Expression of Prion Protein in the Vasculature
    The Expression of Prion Protein in the Vasculature Richard David Starke BSc (Hons) A thesis submitted to the University of London for the degree of Doctor of Philosophy University College London, 2003 ProQuest Number: U643764 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U643764 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract The aim of my thesis was to study the expression of prion protein (PrP^) in the vasculature. The function of PrP^ is unknown but it is thought to refold into a pathogenic form termed PrP^^ which damages neurones in the brain causing transmissible spongiform encephalopathies. I studied the expression of PrP^ in CD34 positive stem cells, reticulocytes, erythrocytes and megakaryocytes. These cells were found to be positive for PrP^ with a general trend for increased expression during megakaryocyte maturation and a decrease in expression during erythropoiesis. Since megakaryocytes were positive for PrP^ I hypothesised that they were the source of platelet PrP^. I studied the expression, location and function of PrP^ in platelets. PrP^ was found in platelet alpha-granules and was transported to the cell surface upon cellular activation.
    [Show full text]
  • Haematopoesis Solarsystem
    Haematopoiesis Peripheral blood Lymph nodes Bone marrow Haematopoietic stem cell B lymphocyte Pro-B Lymphoid-primed multipotent progenitor Common Multipotent lymphoid progenitor progenitor Lymphoblast Monoblast Promonocyte Granulocyte- monocyte Monocyte Common myeloid progenitor progenitor Bone marrow NK-cell Neutrophilic Neutrophilic myelocyte metamyelocyte Neutrophilic Pro-T Myeloblast band cell Neutrophilic granulocyte Promyelocyte Thymus Eosinophilic myelocyte Megakaryocyte-erythroid T lymphocyte progenitor Bone marrow Proerythroblast Eosinophilic metamyelocyte Megakaryoblast Basophilic Eosinophilic myelocyte band cell Basophilic erythroblast Peripheral blood Eosinophilic granulocyte Basophilic metamyelocyte Polychromatic Promegakaryocyte erythroblast Basophilic Orthochromatic band cell erythroblast The illustration of haematopoiesis as a ‘solar system’ model is based on the idea of a high plasticity of haematopoiesis and an intimate relationship Peripheral blood between various types of progenitor cells.* Many progenitors share common transcription factors. The proximity of radial sectors of different cell Megakaryocyte lineages depicts how close the ontogeny of these lineages is. Gradual colour change reflects the potential of early and intermediate progenitors Basophilic to follow different cells’ fates. granulocyte Reticulocyte Reticulated platelet Haematopoietic stem cell Common lymphoid progenitor Granulocyte-monocyte progenitor A true stem cell that has a potential to self-renew The early progenitor committed to lymphoid This intermediate progenitor is committed and differentiate into any lineage of blood cells. lineage. Gives rise to precursors of T and B to monocytic and granulocytic lineages. lymphocytes and natural killer cells. Lymphoid Multipotent progenitor progenitors leave the bone marrow for matu- Megakaryocyte-erythroid progenitor Can give rise to any blood cell lineage. ration in the thymus and lymph nodes. Intermediate progenitor that can only differ- entiate into a red blood cell or megakaryocyte.
    [Show full text]
  • Hematopoiesis
    Hematopoiesis 1. Hemopoietic tissues 2. Stages and sites of hemopoiesis 3. Hematopoiesis: erythropoiesis granulopoiesis megakaryocytopoiesis 4. Regulation of hematopoiesis Hematopoiesis Hemopoiesis, Gr. haima, blood + poiesis, a making (origin and maturation of new blood cells) еrythropoiesis = formation of erythrocytes granulopoiesis = formation of granulocytes mono-/lymphocytopoiesis = formation of agranulocytes megakaryocytopoiesis = formation of platelets Prof. Dr. Nikolai Lazarov 2 Hematopoietic tissues Hemopoietic tissues: blood-forming tissue, consisting of reticular fibers and similarly specialized connective tissue cells of mesenchymal origin that give rise to new blood cells myeloid tissue, Gr. µυєλός, myelos, marrow (red bone marrow) = formation of most of the blood cells: erythrocytes, granulocytes and thrombocytes (platelets) lymphoid tissue (thymus, spleen) = formation of T-lymphocytes, proliferation of B-lymphocytes, immune defense (lymph nodes and associated lymphoid tissue, MALT, GALT, BALT) Prof. Dr. Nikolai Lazarov 3 Periods of hematopoiesis . prenatal hematopoiesis (intraembryonic): mesoblastic (megaloblastic) phase – 14 days (2nd gestational week) yolk sac mesoderm hemocytoblasts hepatolienal phase – 5th to 6th gestational week . postnatal liver erythrocytes hematopoiesis: spleen Er+granulocytes, myeloid phase – lymphocytes (after 5th month) in red bone marrow thymus Т-lymphocytes (textus myeloides) medullary (myeloid) phase – since 4th month red (hematogenous) bone marrow yellow bone marrow
    [Show full text]
  • Regulation of Bone Metabolism by Megakaryocytes in a Paracrine
    www.nature.com/scientificreports OPEN Regulation of bone metabolism by megakaryocytes in a paracrine manner Young-Sun Lee1,5, Mi Kyung Kwak2,3,5, Sung-Ah Moon1, Young Jin Choi1, Ji Eun Baek1, Suk Young Park4, Beom-Jun Kim2, Seung Hun Lee2 & Jung-Min Koh2* Megakaryocytes (MKs) play key roles in regulating bone metabolism. To test the roles of MK-secreted factors, we investigated whether MK and promegakaryocyte (pro-MK) conditioned media (CM) may afect bone formation and resorption. K562 cell lines were diferentiated into mature MKs. Mouse bone marrow macrophages were diferentiated into mature osteoclasts, and MC3T3-E1 cells were used for osteoblastic experiments. Bone formation was determined by a calvaria bone formation assay in vivo. Micro-CT analyses were performed in the femurs of ovariectomized female C57B/L6 and Balb/c nude mice after intravenous injections of MK or pro-MK CM. MK CM signifcantly reduced in vitro bone resorption, largely due to suppressed osteoclastic resorption activity. Compared with pro-MK CM, MK CM suppressed osteoblastic diferentiation, but stimulated its proliferation, resulting in stimulation of calvaria bone formation. In ovariectomized mice, treatment with MK CM for 4 weeks signifcantly increased trabecular bone mass parameters, such as bone volume fraction and trabecular thickness, in nude mice, but not in C57B/L6 mice. In conclusion, MKs may secrete anti-resorptive and anabolic factors that afect bone tissue, providing a novel insight linking MKs and bone cells in a paracrine manner. New therapeutic agents against metabolic bone diseases may be developed from MK-secreted factors. Bone metabolism is regulated mainly by the action of bone-resorbing osteoclasts and bone-forming osteoblasts.
    [Show full text]
  • The Identification of Mature and Immature Leucocytes in Peripheral Blood Smears and Bone Marrow Preparations Is Fundamental To
    The identification of mature and immature blood cells in peripheral blood smears and bone marrow preparations is fundamental to the laboratory diagnosis of haematological disorders. Here, you may review the mature and immature white cells to gain more practice and confidence in their identification. Immature cells are found in peripheral blood in leukaemia. Modified to printer-friendly form from Quensland University of Tehcnology, Our Medical Science pages & University of California Davis School of Medicine) Granulocytes Bone Marrow Peripheral Blood (Neutrophile) Left - Nonsegmented neutrophil Myelocyte (Neutrophile) Metamyelocyte Cell size: 12 -15 -m Cell size: 10-16 -m Cell size: 12 -23 -m N:C ratio: Ratio more reduced, 40% N:C ratio: Ratio more reduced 30 - 40% N:C ratio: 60%, decreasing Cytoplasm: Similar to mature cell Cytoplasm: Similar to mature cell Cytoplasm: Development of Nucleus: Indentation of nucleus Nucleus: Curved, without distinct lobes secondary (specific) granules, some begins; heavy chromatin clumping, Note: Also referred as "band forms" or primary granules may be visible nucleoli not visible "stab cells". Nucleus: Oval or round, with further Right - Segmented Neutrophil clumping, nucleoli no long visible Cell size: 10-16 -m Note: The term myelocyte infers it is a N:C ratio: Ratio more reduced 20 - 30 % neutrophil myelocyte, also found are Cytoplasm: Fine specific granules, pink- eosinophil myelocytes and basophil tan cytoplasm. myelocytes. Nucleus: Segmented nucleus (normal up to 5 lobes) Myeloblast Promyelocyte Cell
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,891,725 Soreq Et Al
    USOO5891725A United States Patent (19) 11 Patent Number: 5,891,725 Soreq et al. (45) Date of Patent: Apr. 6, 1999 54 SYNTHETIC ANTISENSE Gnatt et al., “Expression of alternatively terminated unusual OLIGODEOXYNUCLEOTIDES AND human butyrylcholinesterase meSSenger RNA PHARMACEUTICAL COMPOSITIONS transcripts. " Cancer Research, 50:1983–1987, (1990). CONTAINING THEM Iyer et al., “The automated Synthesis of Sulfur-containing oligodeoxyribonucletodies . J. Org. Chem., 55: 75 Inventors: Hermona Soreq, Rishon Le Zion; 4693-4699 (1990). Haim Zakut, Savyon, both of Israel; Lapidot-Lifson et al., “Cloning and antisense oligodeoxy Fritz Eckstein, Gottingen, Germany nucleotide inhibition of a human homolog . .” Proc. Natl. Acad. Sci., USA, vol.89, pp. 579–583, (1992). 73 Assignee: Yissum Research Development Co. of Lapidot-Lifson et al., “Coamplification of human acetyl the Hebrew Univ. of Jerusalem, cholinesterase and butyrylcholinesterase genes in blood Jerusalem, Israel cells . Proc. Natl. Acad. Sci., USA, Vol. 86, pp. 21 Appl. No.: 318,826 4715-4719 (1989). Layer et al., “Quantitative development and molecular forms 22 PCT Filed: Apr. 15, 1993 of acetyl-and butyrylcholinesterase . 'Journal of Neuro 86 PCT No.: PCT/EP93/00911 chemistry, 49: 175-182 (1987). Lee and Nurse, “Complementation used to clone a human S371 Date: Dec. 1, 1994 homologue of the fission yeast cell cycle control gene cdc2” S 102(e) Date: Dec. 1, 1994 Nature, 327:31–35 (1987). Loke et al., “Characterization of oligonucleotide transport 87 PCT Pub. No.: WO93/21202 into living cells” Proc. Natl. Acad. Sci., USA, 86:3474-3478 PCT Pub. Date: Oct. 26, 1993 (1989). Malinger et al., “Cholinoceptive properties of human pri 30 Foreign Application Priority Data mordial, preantral, and antral oocytes.
    [Show full text]
  • Medical Laboratory Technician--Hematology, Serology, Blood Banking, and Immunohematology (AFSC 90470)
    DOCUMENT RESUME ED 268 334 CE 044 216 AUTHOR Thompson, Joselyn H. TITLE Medical Laboratory Technician--Hematology, Serology, Blood Banking, and Immunohematology (AFSC 90470). INSTITUTION Air Univ., Gunter AFS, Ala. Extension Course Inst. PUB DATE 25 May 84 NOTE 353p.; Supersedes ED 224 893. PUB TYPE Guides Classroom Use Materials (For Learner) (051) EDRS PRICE MF01/PC15 Plus Postage. DESCRIPTORS *Allied Health Occupations Education; Behavioral Objectives; Biomedical Equipment; Correspondence Study; Distance Education; *Laboratory Procedures; *Laboratory Technology; Learning Activities; *Medical Evaluation; Medical Services; *Medical Technologists; Military Personnel; *Military Training; Postsecondary Education IDENTIFIERS Air Force; Blood Transfusion; *Hematology; Immunology; Serology ABSTRACT This three-volume student text is designed foruse by Air Force personnel enrolled in a self-study extensioncourse for medical laboratory technicians. Covered in the individual volumesare hematology (the physiology of blood, complete blood counts and related studies, erythrocyte studies, leukocyte and thrombocyte maturation, and blood coagulation studies); laboratory procedures in blood banking and immunohematology (immunohematology, bloodgroup systems, transfusion and transfusion practices, and the blood donor center); and serology (principles of immunology and serology; agglutination tests; latex-fixation, precipitin, and ASO tests; and serological tests for syphilis). Each volume in the set containsa series of lessons, exercises at the end of
    [Show full text]
  • Integrin Iib Promoter-Targeted Expression of Gene Products In
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 9654–9659, August 1999 Cell Biology Integrin ␣IIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells ʈ DAVID A. WILCOX*†,JOHN C. OLSEN*‡,LORI ISHIZAWA§,MICHAEL GRIFFITH§, AND GILBERT C. WHITE II*†¶ ¶Center for Thrombosis and Hemostasis, Departments of *Medicine and †Pharmacology, and ‡Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC 27599; and §Nexell Therapeutics Inc., Irvine, CA 92618 Communicated by Inder M. Verma, The Salk Institute for Biological Studies, San Diego, CA, June 17, 1999 (received for review March 26, 1999) ABSTRACT Megakaryocyte-specific expression of the blood coagulation, and release granule contents. This regu- platelet-adhesion receptor, integrin ␣IIb␤3, is caused by the lates blood clotting, stimulates wound healing, and mediates presence of regulatory elements of the ␣IIb promoter that platelet aggregation to seal damaged vessels. direct high-level, selective gene transcription early in Megakaryocyte-specific expression of the major platelet- megakaryocytopoiesis. To develop methods for targeted ex- aggregation receptor, integrin ␣IIb␤3, is caused by the pres- pression of transgenes, we transduced human CD34؉ periph- ence of regulatory elements of the ␣IIb promoter that direct eral blood cells with a murine leukemia virus (MuLV) vector high-level, selective gene transcription early in megakaryocy- controlled by the human integrin ␣IIb promoter (nucleotides topoiesis. The ␣IIb promoter has been previously demon- -؊889 to ؉35). A naturally occurring cDNA encoding the PlA2 strated to direct high-level, megakaryocyte-targeted gene tran alloantigen form (Pro33) of the integrin ␤3 subunit was scription in human cell lines (1–3), rat cells (4), and transgenic subcloned into this construct (؊889PlA2␤3) and transduced mice (5, 6).
    [Show full text]